Abiomed closed the most recent trading day at $330.69, moving +0.78% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 0.95%.
Coming into today, shares of the maker of heart devices had lost 0.76% in the past month. In that same time, the Medical sector lost 2.71%, while the S&P 500 lost 4.97%.
Investors will be hoping for strength from ABMD as it approaches its next earnings release, which is expected to be February 7, 2019. The company is expected to report EPS of $0.93, up 32.86% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $194.88 million, up 26.53% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.04 per share and revenue of $771.16 million, which would represent changes of +105.71% and +29.88%, respectively, from the prior year.
Any recent changes to analyst estimates for ABMD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% higher. ABMD is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note ABMD's current valuation metrics, including its Forward P/E ratio of 65.14. For comparison, its industry has an average Forward P/E of 32.04, which means ABMD is trading at a premium to the group.
Investors should also note that ABMD has a PEG ratio of 1.9 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABMD's industry had an average PEG ratio of 2.45 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABMD in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Abiomed (ABMD) Outpaces Stock Market Gains: What You Should Know
Abiomed closed the most recent trading day at $330.69, moving +0.78% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 0.95%.
Coming into today, shares of the maker of heart devices had lost 0.76% in the past month. In that same time, the Medical sector lost 2.71%, while the S&P 500 lost 4.97%.
Investors will be hoping for strength from ABMD as it approaches its next earnings release, which is expected to be February 7, 2019. The company is expected to report EPS of $0.93, up 32.86% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $194.88 million, up 26.53% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.04 per share and revenue of $771.16 million, which would represent changes of +105.71% and +29.88%, respectively, from the prior year.
Any recent changes to analyst estimates for ABMD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% higher. ABMD is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note ABMD's current valuation metrics, including its Forward P/E ratio of 65.14. For comparison, its industry has an average Forward P/E of 32.04, which means ABMD is trading at a premium to the group.
Investors should also note that ABMD has a PEG ratio of 1.9 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABMD's industry had an average PEG ratio of 2.45 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABMD in the coming trading sessions, be sure to utilize Zacks.com.